medigraphic.com

2019, Number 1

<< Back Next >>

Cir Cir 2019; 87 (1)

Morbimortality of pancreatoduenectomy in patients with cancer of pancreas and periampular tumors in the Oncology Hospital of Centro Médico Nacional Siglo XXI from 2008 to 2013

Medrano-Guzmán R, Luna-Castillo M, Chable-Puc WJ, García-Ríos LE, González-Rodríguez D, Nájera-Domínguez FI

Language: Spanish
References: 47
Page: 69-78
PDF size: 273.47 Kb.


ABSTRACT

Introduction: Pancreatic tumors and periampullary tumors have a similar clinical presentation; pancreatoduodenectomy represents the only possibility of cure or of increasing survival; with an average mortality of 5-10% and a morbidity of 20-40%. Objective: To determine the morbidity and mortality secondary to the pancreatoduodenectomy intervention in patients with pancreatic cancer or periampullary tumors in the Oncology Hospital of Centro Médico Nacional Siglo XXI (Mexico City) from 2008 to 2013. Method: Historical, observational and descriptive cohort carried out in the department of sarcomas and tumors of the upper digestive tube of the Oncology Hospital of Centro Médico Nacional Siglo XXI, postoperative pancreatoduodenectomy from 2008 to 2013. Results: We included 71 patients who underwent pancreatoduodenectomy, 47 (66.2%) were fema- le and 24 (33.8%) were male. The average age was 60.3 years. The most common histology was cancer of the Vater’s ampulla (66.2%). The resections were R0 in 95.8% of the cases. Mortality was 4.22% and morbidity was 69%. The most frequent complication was pancreatic fistula (23.9%). In the statistical analysis, perioperative transfusion was associated with surgical complications (p ‹ 0.007). Conclusions: The morbidity of pancreatoduodenectomy is greater than that reported in the literature, however, it does not influence mortality that is similar to that reported in other centers. The number of lymph nodes resected; as well as the percentage of negative margins are those accepted worldwide; It is concluded that this is derived from the experience of the center where these procedures are performed. No factor with statistical significance was found, only the transfusion that increased the complications.


REFERENCES

  1. Hoyos S, Duarte A, Franco G. Evaluación y seguimiento de los pacientes sometidos a operación de Whipple o duodenopancreatectomía cefálica en un hospital de IV nivel de Medellín. Rev Colomb Cir. 2012; 27:114-20.

  2. Steele GD, Osteen RT, Winchester DP. Clinical highlights from the National Cancer Data Base. CA Cancer J Clin. 1994;44:72-80.

  3. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin. 1999;49:8-31.

  4. Páez D, Labonte MJ, Lenz HJ. Pancreatic cancer: medical management. Gastroenterol Clin N Am. 2012;41:189-209.

  5. Yamaguchi K, Enjoji M. Carcinoma of the ampulla of Vater. A clinicopathologic study and pathologic staging of 109 cases of carcinoma and 5 cases of adenoma. Cancer. 1987;59:506-15.

  6. Shah OJ, Mushtaq A, Gagloo MA, Khan IJ, Pancreaticoduodenectomy: a comparison of superior approach with classical Whipple’s technique. Hepatobiliary Pancreat Dis Int. 2013;12:196-203.

  7. Cameron JL, Riall TS, Coleman J. One thousand consecutive pancreaticoduodenectomies. Ann Surg. 2006;244:10-5.

  8. Gouma DJ, van Geenen RC, van Gulik TM. Rates of complications and death after pancreaticoduodenectomy: risk factors and the impact of hospital volume. Ann Surg. 2000;232:786-95.

  9. Klein F, Jacob D, Bahra M. Prognostic factors for long-term survival in patients with ampullary carcinoma: the results of a 15-year observation period after pancreaticoduodenectomy. HPB Surg. 2014;2014:970234.

  10. Winter JM, Cameron JL, Campbell KA. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg. 2006;10:1199-210.

  11. McPhee JT, Hill JS, Whalen GF. Perioperative mortality for pancreatectomy: a national perspective. Ann Surg. 2007;246:246-53.

  12. Kazanjian KK, Hines OJ, Duffy JP. Improved survival following pancreaticoduodenectomy to treat adenocarcinoma of the pancreas: the influence of operative blood loss. Arch Surg. 2008;143:1166-71.

  13. Grobmyer SR, Pieracci FM, Allen PJ. Defining morbidity after pancreaticoduodenectomy: use of a prospective complication grading system. J Am Coll Surg. 2007;204:356-64.

  14. Nitecki SS, Sarr MG, Colby TV. Long-term survival after resection for ductal adenocarcinoma of the pancreas: is it really improving? Ann Surg. 1995; 221 59-66.

  15. Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg. 2003;237:74-85.

  16. Conlon KC, Klimstra DS, Brennan MF. Long-term survival after curative resection for pancreatic ductal adenocarcinoma clinicopathologic analysis of 5-year survivors. Ann Surg. 1996;223:273-9.

  17. Distler M, Rückert F, Hunger M. Evaluation of survival in patients after pancreatic head resection for ductal adenocarcinoma. BMC Surg. 2013;13:12.

  18. Sukharamwala P, Thoens J, Szuchmacher M. Advanced age is a risk factor for post-operative complications and mortality after a pancreaticoduodenectomy: a meta-analysis and systematic review. HPB Surg. 2012;14 649-57.

  19. Sohn TA, Yeo CJ, Cameron JL. Resected adenocarcinoma of the pancreas — 616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567-79.

  20. Millikan KW, Deziel DJ, Silverstein JC. Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas. Am Surg. 1999;65 618-24.

  21. Nitecki SS, Sarr MG, Colby TV. Long-term survival after resection for ductal adenocarcinoma of the pancreas: is it really improving? Ann Surg. 1995;221 59-66.

  22. Enomoto LM, Gusani NJ, Dillon PW. Impact of surgeon and hospital volume on mortality, length of stay, and cost of pancreaticoduodenectomy. J Gastrointest Surg. 2014;18:690-700.

  23. Birkmeyer JD, Siewers AE, Finlayson EV. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346:1128-37.

  24. Rosemurgy AS, Bloomston M, Serafini FM. Frequency with which surgeons undertake pancreaticoduodenectomy determines length of stay, hospital charges, and in-hospital mortality. J Gastrointest Surg. 2001;5:21-6.

  25. Howard JM. Pancreatico-duodenectomy: forty-one consecutive Whipple resections without an operative mortality. Ann Surg. 1968;168:629-40.

  26. Chan C, Franssen B, Rubio A. Pancreaticoduodenectomy in a Latin American country: the transition to a high-volume center. J Gastrointest Surg. 2008;12:527-33.

  27. Balcom JH, Rattner DW, Warshaw. Ten-year experience with 733 pancreatic resections: changing indications, older patients, and decreasing length of hospitalization. Arch Surg. 2001;136:391-8.

  28. Trede M, Schwall G, Saeger HD. Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality. Ann Surg. 1990;211:447-58.

  29. Chan C, Herrera MF, de la Garza. Clinical behavior and prognostic factors of periampullary adenocarcinoma. Ann Surg. 1995;222:632-7.

  30. Jakhmola BCK, Kumar WCA. Whipple’s pancreaticoduodenectomy: outcomes at a tertiary care hospital. MJAFI. 2014;70:321-6.

  31. Böttger TC, Junginger T. Factors influencing morbidity and mortality after pancreaticoduodenectomy: critical analysis of 221 resections. World J Surg. 1999;23:164-71.

  32. Magistrelli P, Antinori A, Crucitti A. Surgical resection of pancreatic cancer. Tumori. 1999;85:22-6.

  33. Benassai G, Mastrorilli M, Quarto G. Factors influencing survival after resection for ductal adenocarcinoma of the head of the pancreas. J Surg Oncol. 2000;73:212-8.

  34. Klinkenbijl JH, Jeekel J, Sahmoud T. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230:776-82.

  35. Neoptolemos JP, Stocken DD, Friess H. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200-10.

  36. Buzaid AC, Cotait F, Rocha CM. Manual de oncología clínica de Brasil. MOC 2012;187-98.

  37. Kalser MH, Ellenberg SS. Adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Arch Surg. 1985; 120:899-903.

  38. Joensuu H, Alanen KA, Klemi P. Doubts on “curative” resection of pancreatic cancer. Lancet. 1989;1:953-4.

  39. Petrek JA, Sandberg WA, Bean PK. Can survival in pancreatic adenocarcinoma be predicted by primary size or stage? Am Surg. 1985;51:42-6.

  40. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg. 1993;165:68-72.

  41. Cameron JL, Crist DW, Sitzmann JV. Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg. 1991;161:120-4.

  42. Konstantinidis IT, Warshaw AL, Allen JN. Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a “true” R0 resection? Ann Surg. 2013;257:731-6.

  43. Delpero JR, Bachellier P, Regenet N. Pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a French multicentre prospective evaluation of resection margins in 150 evaluable specimens. HPB Surg. 2014;16:20-33.

  44. Eeson G, Chang N, McGahan CE. Determination of factors predictive of outcome for patients undergoing a pancreaticoduodenectomy of pancreatic head ductal adenocarcinomas. HPB Surg. 2012;14:310-6.

  45. Tempero MA, Malafa MP, Behrman SW, Benson AB, Casper ES, Chiorean EG, et al. Pancreatic adenocarcinoma. J Natl Compr Canc Netw. 2014;12:1083-93.

  46. Orr RK. Outcomes in pancreatic cancer surgery. Surg Clin N Am. 2010; 90:219-34.

  47. Warshaw AL, Thayer SP. Pancreaticoduodenectomy. J Gastrointest Surg. 2004;8:1-5.




2020     |     www.medigraphic.com